Conflict of interest statement: Conflict of Interest Disclosures: Drs 
Skljarevski, Oakes, Zhang, Ferguson, Martinez, Camporeale, Johnson, Shan, 
Carter, and Schacht are full-time employees of Eli Lilly and Company and/or one 
of its subsidiaries, and are stockholders. Dr Goadsby reports receiving 
consultant fees from Allergan, Amgen, and Eli-Lilly and Company; and personal 
fees from Akita Biomedical, Alder Biopharmaceuticals, Autonomic Technologies 
Inc, Avanir Pharma, Cipla Ltd, Colucid Pharmaceuticals, Ltd, Dr Reddy's 
Laboratories, eNeura, Electrocore LLC, Novartis, Pfizer Inc, Promius Pharma, 
Quest Diagnostics, Scion, Teva Pharmaceuticals, Trigemina Inc; MedicoLegal work, 
Journal Watch, UptoDate, and Oxford University Press. In addition, Dr Goadsby 
has a patent magnetic stimulation for headache pending assigned to eNeura. Dr 
Dodick has received compensation from serving on advisory boards and/or 
consulting within the past 5 years for Allergan, Amgen, Alder, Arteaus, Pfizer, 
Colucid, Merck, NuPathe, Eli Lilly and Company, Autonomic Technologies, Ethicon 
J&J, Zogenix, Supernus, Labrys, Boston Scientific, Medtronic, St Jude, 
Bristol-Myers Squibb, Lundbeck, Impax, MAP, Electrocore, Tonix, Novartis, Teva, 
Alcobra, Zosano, Insys, GBS/Nocira, Acorda, eNeura, Charleston Laboratories, 
Gore, Biohaven, Bioventric, Magellan, Theranica, Xenon, and Dr Reddy’s/Promius 
Pharma. Dr Dodick owns equity in Epien, GBS/Nocira, Second Opinion, Healint, and 
Theranica. Dr Dodick has received funding for travel, speaking, editorial 
activities, or royalty payments from IntraMed, SAGE Publishing, Sun Pharma, 
Allergan, Oxford University Press, American Academy of Neurology, American 
Headache Society, West Virginia University Foundation, Canadian Headache 
Society, HealthLogix, Universal Meeting Management, WebMD, UptoDate, Medscape, 
Oregon Health Science Center, Albert Einstein University, University of Toronto, 
Starr Clinical, Decision Resources, Synergy, MedNet LLC, Peer View Institute for 
Medical Education, Medicom, Chameleon Communications, Academy for Continued 
Healthcare Learning, Haymarket Medical Education, Global Scientific 
Communications, HealthLogix, Miller Medical, MeetingLogiX, and Wiley Blackwell. 
Dr Dodick, through his employer, has consulting use agreements with 
NeuroAssessment Systems and Myndshft. He holds board of director positions with 
King-Devick Technologies and Epien Inc. He holds the following Patent 
17189376.1-1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine 
Prophylaxis (no compensation). No other disclosures are reported.